Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi: 10.1002/jcph.1693. Epub 2020 Jul 27.
Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.
目前，世界正面临一种新型的贝塔冠状病毒的大流行，这种病毒被称为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。急性呼吸窘迫综合征（ARDS）是 SARS-CoV-2 最具破坏性的并发症。有研究表明，细胞因子释放综合征和主要的白细胞介素（IL）-6 在与新型 2019 年冠状病毒病（COVID-19）相关的 ARDS 的病理生理学中发挥着核心作用。尽管该疾病在全球范围内紧急，但目前尚无针对该疾病的经证实的治疗方法。托珠单抗是一种针对 IL-6 的潜在重组单克隆抗体，目前正在研究用于治疗 COVID-19 患者的 ARDS。鉴于这些情况，我们回顾了托珠单抗在治疗 COVID-19 相关 ARDS 方面的潜在治疗作用及其重要临床问题的现有证据。
